GenSight Biologics declares efficacy and safety of LUMEVOQ four years post-injection

Nuvalent's NVL-520 receives FDA breakthrough therapy designation

Nuvalent commences NVL-655 phase 2 clinical trial in subjects with NSCLC and other solid tumours

GC Biopharma's GC1130A receives EMA Orphan Drug Designation

Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval

Newron enrols 290 patients in schizophrenia study

Vistagen granted European patent for AV-101 to treat neuropathic pain

GenSight Biologics reports business and financial update

Alora Pharmaceuticals announces Relexxii commercial launch

IGC Pharma granted patent for Alzheimer's drug formulation

NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials

Rznomics's RZ-001receives US FDA Fast Track Designation

Plus Therapeutics secures FDA Orphan Drug Designation for rhenium (186Re) obisbemeda in breast cancer with leptomeningeal metastases

Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials

Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation